MedTrace Logo

HPV Prevalence in Transpersons - a Prospective Study

NCT04864951 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 203

Last updated 2023-03-15

No results posted yet for this study

Summary

In this study, Human Papilloma Virus (HPV) prevalence will be determined once in the urine of 200 trans people. In addition, subjects will be asked to complete a questionnaire about their sexual orientation, which is adapted from the largest published study.

Conditions

  • Papillomavirus Infection
  • Transsexualism

Interventions

DIAGNOSTIC_TEST

Colli-Pee urine collection device

first-void urine is collected using Colli-Pee and subsequently analyzed using Anyplex™ II HPV HR Detection from Seegene.

OTHER

Survey

Subjects are asked to complete a survey that includes questions about sexual orientation, hormone therapy, gender reassignment surgery, number of sexual partners, HPV vaccination, and smoking

Sponsors & Collaborators

  • Sophie Pils

    lead OTHER

Principal Investigators

  • Elmar Joura, MD · Medical University of Vienna, Department of Obstetrics and Gynecology

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-02
Primary Completion
2021-11-01
Completion
2021-11-01

Countries

  • Austria
  • Slovenia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04864951 on ClinicalTrials.gov